Drug Trial Radar · NCT04565574
A Study to Assess the Effect of Food Intake and Drug-drug Interactions of E7090 When Co-administered With Rabeprazole or Rifampin in Healthy Participants
Last checked: Nov 19, 2026Latest source record: Nov 1, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
42
Actual
Start
Oct 16, 2020
Primary completion
Mar 31, 2021
Study completion Mar 31, 2021
Sponsor
- Lead sponsor
- Eisai Co., Ltd.Eisai
- Sponsor type
- Industry
- First posted
- Sep 25, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will have three parts: Part A, Part B, and Part C. The primary purpose of Part A is to evaluate the effect of food on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part B is to evaluate the effects of rabeprazole (a gastric acid-reducing agent) on the rate and extent of E7090 absorption following single oral doses of E7090 in healthy participants, Part C is to evaluate the effects of rifampin (a strong Cytochrome P450 3A \[CYP3A\] inducer) on pharmacokinetics (PK) of single oral doses of E7090 in healthy participants.
Conditions
- Healthy Participants
Interventions
E7090Drug
Oral tablet.
Rabeprazole 20 mgDrug
Rabeprazole 20 mg (2 tablets, each of 10 mg) oral tablet.
Rifampin 600 mgDrug
Rifampin 600 mg (4 capsules, each of 150 mg) oral capsule.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax: Maximum Observed Plasma Concentration of E7090Time frame: 0-144 hours post-dose following E7090 administration
- AUC(0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration of E7090Time frame: 0-144 hours post-dose following E7090 administration
- AUC(0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time of E7090Time frame: 0-144 hours post-dose following E7090 administration
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Eisai trial site #1
Minatoku, Tokoyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.